HIT-Meso: Hemi-thoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma
Trial Summary:
HIT-MESO is a Phase III randomised-controlled study to assess the impact of proton beam therapy (PBT) on patients with unilateral malignant pleural mesothelioma (MPM). The study aims to evaluate whether PBT improves progression-free survival (PFS) and overall survival (OS), while also examining its effects on quality of life and cost-effectiveness compared to standard care. The trial will recruit 148 patients across 18-20 UK sites, with randomisation into two arms. Control arm, standard active surveillance, intervention arm will receive PBT to the hemi-thorax, delivering 50Gy in 25 fractions, with an integrated boost to 60Gy for visible tumours.
RT QA Summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire | ||
| Outlining Benchmark Case |  | 1 Case | |
| Planning Benchmark Case | | 1 Case | |
| Dummy Run | |||
| During Accrual | Individual Case Review | | Prospective: First three cases outlining and planning Retrospective: Patients 4-10 |
| Data collection | | All patients | |
| Dosimetry Audit | | ||
| QA Streamlining |
RTTQA Contact: enh-tr.hit-mesoqa@nhs.net
Chief Investigator: Dr Crispin Hiley
RT Lead: Dr David Woolf
Sponsor: University College London ctc.hit-meso@ucl.ac.uk
Funder: Asthma + Lung UK and Mesothelioma UK